Life Science News

Dexcom has announced its Dexcom G5 Mobile CGM system has been approved by Health Canada for “non-adjunctive” use by diabetics patients aged two and up.

Dexcom (NASDAQ: DXCM) has announced its Dexcom G5 Mobile CGM system has been approved by Health Canada for “non-adjunctive” use by diabetics patients aged two and up.
According to the press release:

“The ‘non-adjunctive’ indication enables the use of the Dexcom G5 Mobile CGM system as a replacement to fingerstick glucose testing for diabetes treatment decisions, making it a significant new standard of care in diabetes management. This approval means that diabetes patients and their physicians can now make treatment decisions based on data reported by the Dexcom G5 Mobile CGM system alone, without the use of painful fingersticks associated with blood glucose meters.”

CEO Kevin Sayer said the following:

“The new indication in Canada for the Dexcom G5 Mobile CGM system is an astounding milestone for people with diabetes and is a critical step forward for advancing diabetes technology to drastically change diabetes management. Now, people with diabetes in Canada who use the Dexcom G5 Mobile CGM system can make treatment decisions without having to perform multiple fingersticks daily, which has posed a significant barrier to properly managing diabetes in the past.”

Read the full press release here.

MARKETS

Markets
TSX18833.66-244.98
TSXV616.47-9.87
DOW30795.55-233.76
S&P 5003793.49-25.34
NASD11065.72-112.17
ASX6700.20-63.40

COMMODITIES

Commodities
Gold1807.07-11.76
Silver20.36-0.38
Copper3.70-0.08
Palladium1938.50-23.50
Platinum904.83-14.17
Oil106.05-3.73
Heating Oil3.83-0.12
Natural Gas5.66-0.84

DOWNLOAD FREE REPORTS

×